Labcorp Holdings Inc.
NYSE:LHMedical - Diagnostics & Research
-$3.46 today
- Market cap
- $30.11B
- Beta
- 0.88
- P/E (TTM)
- 22.4
- EPS (TTM)
- $11.44
- Dividend yield
- 1.12%
Volume 0.69M
Average 0.63M
LH Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Labcorp Holdings Inc.NYSE: LH
Revenue · Q2 FY2026 · quarter ended Jun 2026
Revenue grows in line with its trailing trend
Q2 FY2026 revenue of $3.73B rose 5.8% year over year, behind the +6.4% change in trailing-twelve-month revenue. Sequentially, it rose 5.5% from the prior quarter. Over 3 fiscal years it compounded at +5.6% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 8 analysts of $14.83B (+6.3%) for the fiscal year ending Dec 2026, a pace similar to FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $3.73B+5.5% QoQ
- Last fiscal yearDec 2025
- $13.95B+7.2% YoY
- LTMJun 2026
- $14.35B+6.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +5.8% | +5.5% | -0.3 pp |
| 1 year | +7.2% | +6.3% | -1.0 pp |
| 3-year CAGR | +5.6% | +5.6% | +0.0 pp |
| 5-year CAGR | +1.8% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 13.95B USD
- Year-over-year change
- +7.2%
- 4-year CAGR
- +1.5%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.95B | +7.2% |
| FY2024 | 2024-12-31 | 13.01B | +7.0% |
| FY2023 | 2023-12-31 | 12.16B | +2.5% |
| FY2022 | 2022-12-31 | 11.86B | -9.7% |
| FY2021 | 2021-12-31 | 13.14B | — |
Revenue vs competitors
How LH compares with its peers on the latest reported figures
- LH's LTM Jun 2026 revenue of $14.35B is the 2nd highest of the 7 companies compared; the peer median is $2.4B.
- Its year-over-year change of +6.4% is the 6th highest of 7, against a peer median of +16.1%.
- Over three fiscal years its annual growth of +5.6% compares with a peer median of +16.7%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | $47.35B | +8.3% | -0.3% | |
| LTM Jun 2026 | $14.35B | +6.4% | +5.6% | |
| LTM Sep 2026 | $11.84B | +9.1% | +3.7% | |
| LTM Jun 2026 | $2.71B | +37.8% | +41.1% | |
| LTM Jun 2026 | $2.1B | +3.0% | -0.8% | |
| LTM Sep 2026 | $1.28B | +41.7% | +29.8% | |
| LTM Jun 2026 | $165.26M | +23.1% | +38.4% | |
| Peer median (excluding LH) | $2.4B | +16.1% | +16.7% | |
Competitors are the stored peer set for LH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 13.14B | 11.86B | 12.16B | 13.01B | 13.95B |
| Cost of Revenue | 8.14B | 8.16B | 8.8B | 9.38B | 10.22B |
| Gross Profit | 4.99B | 3.71B | 3.36B | 3.62B | 3.73B |
| Gross Margin | 38.0% | 31.3% | 27.7% | 27.9% | 26.8% |
| Research & Development | 0 | 0 | 2M | 0 | 0 |
| Selling, General & Admin | 1.69B | 2B | 2.02B | 2.23B | 2.22B |
| Operating Expenses | 1.94B | 2.27B | 2.64B | 2.54B | 2.22B |
| Depreciation & Amortization | 577M | 537.2M | 577.3M | 643.5M | 681.1M |
| EBITDA | 3.68B | 1.95B | 1.35B | 1.81B | 2.01B |
| EBITDA Margin | 28.0% | 16.5% | 11.1% | 13.9% | 14.4% |
| Operating Income | 3.05B | 1.44B | 725.6M | 1.09B | 1.52B |
| Operating Margin | 23.2% | 12.1% | 6.0% | 8.4% | 10.9% |
| Interest Income | 0 | 0 | 0 | 0 | 15.2M |
| Interest Expense | 211.8M | 179.8M | 199.6M | 208.3M | 224.1M |
| Other Income / Expenses | (161M) | (199.1M) | (156.7M) | (127.2M) | (408.7M) |
| Income Before Tax | 2.89B | 1.24B | 568.9M | 959.5M | 1.11B |
| Pre-Tax Margin | 22.0% | 10.4% | 4.7% | 7.4% | 7.9% |
| Income Tax Expense | 690M | 233.9M | 188.5M | 212.4M | 229.8M |
| Net Income | 2.38B | 1.28B | 418M | 746M | 876.5M |
| Net Margin | 18.1% | 10.8% | 3.4% | 5.7% | 6.3% |
| EPS (Basic) | 24.58 | 14.04 | 4.80 | 8.89 | 10.54 |
| EPS (Diluted) | 24.38 | 13.96 | 4.77 | 8.84 | 10.46 |
| Weighted Avg Shares | 96.7M | 91.1M | 87.1M | 83.9M | 83.2M |
| Weighted Avg Shares (Diluted) | 97.5M | 91.6M | 87.6M | 84.4M | 83.8M |
Labcorp Holdings Inc.
NYSE:LH
Intrinsic Alpha fair value
Locked
Current Price
$370.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.